Genomic Biomarkers to Predict Resistance to Hypomethylating Agents in Patients With Myelodysplastic Syndromes Using Artificial Intelligence

PURPOSE: We developed an unbiased framework to study the association of several mutations in predicting resistance to hypomethylating agents (HMAs) in patients with myelodysplastic syndromes (MDS), analogous to consumer and commercial recommender systems in which customers who bought products A and...

Descripción completa

Detalles Bibliográficos
Autores principales: Nazha, Aziz, Sekeres, Mikkael A., Bejar, Rafael, Rauh, Michael J., Othus, Megan, Komrokji, Rami S., Barnard, John, Hilton, Cameron B., Kerr, Cassandra M., Steensma, David P., DeZern, Amy, Roboz, Gail, Garcia-Manero, Guillermo, Erba, Harry, Ebert, Benjamin L., Maciejewski, Jaroslaw P.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: American Society of Clinical Oncology 2019
Materias:
Original Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6818517/
https://www.ncbi.nlm.nih.gov/pubmed/31663066
http://dx.doi.org/10.1200/PO.19.00119

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6818517/
https://www.ncbi.nlm.nih.gov/pubmed/31663066
http://dx.doi.org/10.1200/PO.19.00119

Ejemplares similares